BioSoteria Drug Safety Newsletter Reaches Milestone

Share Article

BioSoteria announced today that it now has more than 1000 subscribers to DSI: Drug Safety Intelligence, a free opt-in email that summarizes the week's most important stories related to drug safety, adverse events and pharmaceutical risk management. DSI subscribers are stakeholders in pharmacovigilance from the United States, Europe, and Asia, and contribute to biopharmaceutical, medical device and consumer health companies, research institutions, hospitals, pharmacies, regulatory agencies, and contract research organizations.

DSI: Drug Safety Intelligence - The Weekly Newsletter from BioSoteria

In my role at InterMune, I must stay up-to-date with the latest news in the world of pharmaceutical safety

BioSoteria, Inc., a drug safety services and training firm, announced today that it now has more than 1000 subscribers to its weekly newsletter DSI: Drug Safety Intelligence. The email publication reached the milestone after eighteen months of distribution, quadrupling the original mailing list.

Initiated on March 20, 2008, DSI: Drug Safety Intelligence is a free weekly opt-in email that summarizes the week's most important stories from around the world related to drug safety, adverse events and pharmaceutical risk management. The BioSoteria editorial team searches more than 10,000 news sources with a finely tuned drug safety filter. News stories are summarized in an abstract and delivered directly to subscribers' email boxes every Thursday.

"In my role at InterMune, I must stay up-to-date with the latest news in the world of pharmaceutical safety," said Sasan Sabrdaran, MD, Director of Drug Safety Risk Management at InterMune, Inc. "For the past year and a half, I have been relying on Drug Safety Intelligence as one of my resources for getting this news. I have always found the information relevant, useful, to-the-point and just enough. Like everything else that BioSoteria does, it is a great contribution to the field of drug safety and ultimately to the safety of patients."

DSI subscribers are stakeholders in pharmacovigilance from the United States, Europe, and Asia. They contribute to biopharmaceutical, medical device and consumer health companies, research institutions, hospitals, pharmacies, regulatory agencies, and contract research organizations. To subscribe to DSI, please visit the company's website and click on Newsletter Sign Up.

DSI now offers pharmacovigilance solution providers a place to advertise to a highly focused and responsive audience. For more information on banner ad opportunities, please contact BioSoteria at 1-866-660-5553, extension 13.

About BioSoteria, Inc.
BioSoteria provides innovative drug safety services and education to the biopharmaceutical industry and healthcare community. The company offers a wide range of pharmacovigilance services throughout the product lifecycle, including premarketing clinical safety surveillance, postmarketing safety monitoring, and risk management programs. BioSoteria-sponsored training and knowledge-sharing programs include eLadder(TM) Safety, the first comprehensive drug safety training curriculum delivered in a true eLearning environment; the annual Pacific Drug Safety Summit, which for the last three years has been the largest pharmacovigilance conference held in the Western United States; and the weekly DSI: Drug Safety Intelligence newsletter.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michelle Flewell
BioSoteria, Inc.
1-866-660-5553 ext. 13
Email >
Visit website